Holen Sie sich die Stockscreener-App
3.41
2.29%
-0.08
Handel nachbörslich:
3.32
-0.09
-2.64%
Schlusskurs vom Vortag:
$3.49
Offen:
$3.41
24-Stunden-Volumen:
127.62K
Relative Volume:
3.32
Marktkapitalisierung:
$82.44M
Einnahmen:
$37.79M
Nettoeinkommen (Verlust:
$-10.38M
KGV:
-4.6712
EPS:
-0.73
Netto-Cashflow:
$-1.00M
1W Leistung:
+33.73%
1M Leistung:
-40.28%
6M Leistung:
+52.91%
1J Leistung:
+135.17%
1-Tages-Spanne:
$3.30
$3.635
1-Wochen-Bereich:
$2.52
$3.76
52-Wochen-Spanne:
$1.04
$7.25
Cumberland Pharmaceuticals Inc Stock (CPIX) Company Profile
Firmenname
Cumberland Pharmaceuticals Inc
Sektor
Telefon
615-255-0068
Adresse
2525 WEST END AVENUE, NASHVILLE,, TN
Vergleichen Sie CPIX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CPIX
Cumberland Pharmaceuticals Inc
|
3.41 | 82.44M | 37.79M | -10.38M | -1.00M | -0.73 |
|
RGC
Regencell Bioscience Holdings Ltd
|
10.36 | 303.95B | 0 | -5.87M | -767.30K | -0.45 |
|
ZTS
Zoetis Inc
|
159.08 | 74.39B | 9.29B | 2.52B | 2.28B | 5.57 |
|
HLN
Haleon Plc Adr
|
10.26 | 48.97B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.42 | 47.39B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.05 | 20.17B | 16.54B | -1.64B | 749.00M | -1.45 |
Cumberland Pharmaceuticals Inc Stock (CPIX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2012-11-12 | Bestätigt | UBS | Neutral |
| 2011-02-01 | Bestätigt | UBS | Neutral |
| 2010-12-16 | Herabstufung | UBS | Buy → Neutral |
| 2010-08-17 | Herabstufung | Jefferies | Buy → Hold |
| 2010-08-17 | Bestätigt | Morgan Joseph | Buy |
| 2010-08-17 | Bestätigt | UBS | Buy |
| 2010-05-14 | Bestätigt | Morgan Joseph | Buy |
Alle ansehen
Cumberland Pharmaceuticals Inc Aktie (CPIX) Neueste Nachrichten
Asthma Market to Expand Significantly by 2034, States - openPR.com
Asthma Market to Expand Significantly by 2034, States DelveInsight Report | GSK, AB Science, Areteia Therapeutics, ARS Pharma, AstraZeneca, Pieris Pharma, Sanofi, Cumberland Pharma, Genentech - Barchart.com
Two Sigma Investments LP Has $89,000 Stake in Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) - Defense World
Cumberland Pharmaceuticals (NASDAQ:CPIX) Shares Cross Above Two Hundred Day Moving Average – Here’s Why - Defense World
Cumberland pharmaceuticals director Kenneth Krogulski acquires $4,824 in stock By Investing.com - Investing.com South Africa
Cumberland pharmaceuticals director Kenneth Krogulski acquires $4,824 in stock - Investing.com
Dilated Cardiomyopathy Market Witnesses Robust Growth During the Study Period (2020–2034) Amid Advancements in Cardiovascular Therapies | DelveInsight - GlobeNewswire Inc.
Cumberland Pharmaceuticals (NASDAQ:CPIX) Share Price Passes Above 200 Day Moving Average – Time to Sell? - Defense World
Investors in Cumberland Pharmaceuticals (NASDAQ:CPIX) have seen splendid returns of 235% over the past year - Yahoo
NEW STUDY FINDS CALDOLOR® SAFE AND EFFECTIVE FOR OPIOID-SPARING PAIN MANAGEMENT IN OLDER ADULTS - PR Newswire
Cumberland Pharmaceuticals (NASDAQ:CPIX) Share Price Passes Above Two Hundred Day Moving Average – Here’s Why - Defense World
Q&A: Cumberland Pharmaceuticals CEO A.J. Kazimi weighs in on industry challenges, strengths - The Business Journals
Cumberland CEO A.J. Kazimi: Pharmaceutical tariffs would be 'concerning' - The Business Journals
Dimensional Fund Advisors LP Cuts Stock Position in Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) - Defense World
Cumberland Pharmaceuticals Reports 38% Revenue Growth in Q1 2025 - The Victoria Advocate
Cumberland, Qureight Collaborate on Lung Disease Treatment Trial - marketscreener.com
CUMBERLAND PHARMACEUTICALS PARTNERS WITH QUREIGHT TO ADVANCE INNOVATIVE IDIOPATHIC PULMONARY FIBROSIS TREATMENT RESEARCH - PR Newswire
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Q1 2025 Earnings Call Transcript - Insider Monkey
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Held Back By Insufficient Growth Even After Shares Climb 30% - simplywall.st
Cumberland Pharmaceuticals Leverages AI Technology to Transform IPF Treatment Research in Major Clinical Trial - Stock Titan
Cumberland Pharmaceuticals Reports Strong Q1 2025 Earnings - TipRanks
Cumberland Pharmaceuticals (NASDAQ:CPIX) Stock Rating Upgraded by StockNews.com - Defense World
Cumberland Pharmaceuticals Reports Strong Q1 2025 Growth - TipRanks
Cumberland Pharmaceuticals Inc (CPIX) Q1 2025 Earnings Call Highlights: Strong Revenue Growth ... By GuruFocus - Investing.com Canada
Cumberland: Q1 Earnings Snapshot - MySA
Cumberland Pharmaceuticals Inc Reports Q1 2025 Earnings: EPS at $0.16, Revenue Hits $11.7 Million - GuruFocus
Earnings call transcript: Cumberland Pharmaceuticals sees Q1 2025 revenue jump 38% - Investing.com
Cumberland Pharmaceuticals Inc.Common Stock (NQ: CPIX - FinancialContent
Renaissance Technologies LLC Sells 21,000 Shares of Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) - Defense World
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q1 2025 FINANCIAL RESULTS & COMPANY UPDATE - marketscreener.com
Cumberland Pharmaceuticals Q1 Earnings Call: Key Updates from Specialty Drug Portfolio Coming May 6 - Stock Titan
Cumberland Pharmaceuticals Shareholders Approve Key Proposals By Investing.com - Investing.com India
Cumberland Pharmaceuticals Shareholders Approve Key Proposals - Investing.com
Press Release Distribution & PR Platform - ACCESS Newswire
Cumberland Pharmaceuticals Inc. to Host Earnings Call - ACCESS Newswire
Cumberland Pharmaceuticals' (NASDAQ:CPIX) growing losses don't faze investors as the stock swells 18% this past week - simplywall.st
Cumberland Pharmaceuticals (NASDAQ:CPIX) Stock Price Crosses Above 200 Day Moving Average – Here’s Why - Defense World
Cumberland Pharmaceuticals director Caroline Young acquires $383 in common stock - Investing.com Australia
Cumberland Pharmaceuticals director Kenneth Krogulski acquires $4,548 in stock By Investing.com - Investing.com South Africa
Cumberland Pharmaceuticals director James Jones buys shares worth $880 By Investing.com - Investing.com South Africa
Cumberland Pharmaceuticals director Kenneth Krogulski acquires $4,548 in stock - Investing.com
Cumberland Pharmaceuticals CEO A.J. Kazimi acquires $880 in common stock - Investing.com
Cumberland Pharmaceuticals director James Jones buys shares worth $880 - Investing.com India
Cumberland Pharmaceuticals (NASDAQ:CPIX) Stock Price Passes Above 200 Day Moving Average – What’s Next? - Defense World
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
FIGHT DMD trial results selected for late-breaking presentation at MDA clinical & scientific conference - Marketscreener.com
Breakthrough DMD Heart Disease Treatment Achieves 5.4% Function Boost While Controls Decline - Stock Titan
FIGHT DMD Trial Results Selected for Late-Breaking Presentation at MDA Clinical & Scientific Conference - PR Newswire
Finanzdaten der Cumberland Pharmaceuticals Inc-Aktie (CPIX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.01%
0.40%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):